公开(公告)号：US20080025977A1

公开(公告)日：2008-01-31

申请号：US11807681

申请日：2007-05-30

申请人： David Young ,  Helen Findlay ,  Susan Hahn ,  Lisa Cechetto ,  Luis de Cruz

发明人： David Young ,  Helen Findlay ,  Susan Hahn ,  Lisa Cechetto ,  Luis de Cruz

IPC分类号： A61K39/395 ,  A61P43/00 ,  C07K16/18 ,  G01N33/53

CPC分类号： C07K16/2896 ,  A61K2039/505 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/734 ,  G01N33/57492 ,  G01N2333/70596

摘要： This invention relates to the staging, diagnosis and treatment of cancerous diseases (both primary tumors and tumor metastases), particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more CDMAB/chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays, which utilize the CDMAB of the instant invention. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells.

摘要翻译： 本发明涉及癌性疾病（原发性肿瘤和肿瘤转移）的分期，诊断和治疗，特别是涉及肿瘤细胞的细胞毒性的介导; 并且最特别地涉及可选地与一种或多种CDMAB /化学治疗剂组合使用癌性疾病修饰抗体（CDMAB）作为起始细胞毒性应答的手段。 本发明还涉及利用本发明的CDMAB的结合测定法。 抗癌抗体可以与毒素，酶，放射性化合物，细胞因子，干扰素，靶或报告物部分和血细胞结合。

公开(公告)号：US20060140963A1

公开(公告)日：2006-06-29

申请号：US11361153

申请日：2006-02-24

申请人： David Young ,  Helen Findlay ,  Susan Hahn ,  Lisa Cechetto ,  Luis da Cruz

发明人： David Young ,  Helen Findlay ,  Susan Hahn ,  Lisa Cechetto ,  Luis da Cruz

IPC分类号： G01N33/574 ,  A61K39/395 ,  C07K16/30

CPC分类号： C07K16/2896 ,  A61K2039/505 ,  C07K16/30 ,  C07K16/303 ,  C07K2317/24 ,  G01N33/57492 ,  G01N2333/70596

摘要： This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays which utilize the CDMAB of the instant invention.

公开(公告)号：US20070202042A1

公开(公告)日：2007-08-30

申请号：US11709457

申请日：2007-02-22

申请人： David Young ,  Helen Findlay ,  Susan Hahn ,  Lisa Cechetto ,  Fortunata McConkey ,  Daad Sayegh

发明人： David Young ,  Helen Findlay ,  Susan Hahn ,  Lisa Cechetto ,  Fortunata McConkey ,  Daad Sayegh

IPC分类号： A61K51/00 ,  A61K38/21 ,  A61K39/395 ,  C07K16/30 ,  C07K16/46

CPC分类号： C07K16/30 ,  A61K38/21 ,  A61K47/6851 ,  A61K51/1045 ,  A61K2039/505

摘要： The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells.

摘要翻译： 本发明涉及使用新颖的筛选范例制备癌性疾病修饰抗体的方法。 通过使用癌细胞细胞毒性分离抗癌抗体作为终点，该方法使得可能产生用于治疗和诊断目的的抗癌抗体。 抗体可用于帮助分期和诊断癌症，并可用于治疗原发性肿瘤和肿瘤转移。 抗癌抗体可以与毒素，酶，放射性化合物，细胞因子，干扰素，靶或报告物部分和血细胞结合。

公开(公告)号：US20060216233A1

公开(公告)日：2006-09-28

申请号：US11364013

申请日：2006-02-28

申请人： David Young ,  Helen Findlay ,  Susan Hahn ,  Lisa Cechetto ,  Fortunata McConkey

发明人： David Young ,  Helen Findlay ,  Susan Hahn ,  Lisa Cechetto ,  Fortunata McConkey

IPC分类号： A61K51/00 ,  G01N33/574 ,  A61K39/395 ,  C12N5/06 ,  C07K16/30 ,  C07K16/46

CPC分类号： C07K16/2884 ,  A61K47/6849 ,  A61K47/6897 ,  A61K49/0013 ,  A61K49/0058 ,  A61K2039/505 ,  B82Y5/00 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/73 ,  G01N33/5082 ,  G01N33/574 ,  G01N33/57492 ,  G01N2333/70585

摘要： This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays which utilize the CDMAB of the instant invention.

摘要翻译： 本发明涉及癌症的诊断和治疗，特别涉及肿瘤细胞的细胞毒性的介导; 并且最特别地涉及使用任选与一种或多种化学治疗剂组合的癌性疾病修饰抗体（CDMAB）作为起始细胞毒性应答的手段。 本发明还涉及利用本发明的CDMAB的结合测定法。

公开(公告)号：US20070031428A1

公开(公告)日：2007-02-08

申请号：US11496669

申请日：2006-07-31

申请人： David Young ,  Susan Hahn ,  Lisa Cechetto

发明人： David Young ,  Susan Hahn ,  Lisa Cechetto

IPC分类号： A61K39/395 ,  G01N33/574 ,  C12N5/06 ,  C07K16/30

CPC分类号： C07K16/30 ,  A61K49/0041 ,  A61K49/0058 ,  A61K2039/505 ,  C07K16/3046 ,  C07K16/3069 ,  C07K2317/73 ,  G01N33/574 ,  G01N33/57415 ,  G01N33/57419 ,  G01N33/57434 ,  G01N33/57449

摘要： The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.

公开(公告)号：US20070031427A1

公开(公告)日：2007-02-08

申请号：US11496457

申请日：2006-07-31

申请人： David Young ,  Susan Hahn ,  Lisa Cechetto

发明人： David Young ,  Susan Hahn ,  Lisa Cechetto

IPC分类号： A61K39/395 ,  G01N33/574 ,  C12N5/06 ,  C07K16/30

CPC分类号： G01N33/57492 ,  A61K2039/505 ,  C07K16/30 ,  C07K16/3046 ,  C07K2317/73 ,  G01N33/57415 ,  G01N33/57419 ,  G01N33/57434 ,  G01N33/57438

摘要： The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.

公开(公告)号：US20050191305A1

公开(公告)日：2005-09-01

申请号：US11067366

申请日：2005-02-25

申请人： David Young ,  Susan Hahn ,  Lisa Cechetto

发明人： David Young ,  Susan Hahn ,  Lisa Cechetto

IPC分类号： A61K39/395 ,  A61K51/10 ,  A61P35/00 ,  C07K16/18 ,  C07K16/30 ,  C12N5/12 ,  C12N5/18 ,  C12Q1/68 ,  G01N33/574

CPC分类号： C07K16/3069 ,  A61K2039/505 ,  C07K16/30 ,  C07K16/3046

摘要： The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.

公开(公告)号：US20070031429A1

公开(公告)日：2007-02-08

申请号：US11496678

申请日：2006-07-31

申请人： David Young ,  Susan Hahn ,  Lisa Cechetto

发明人： David Young ,  Susan Hahn ,  Lisa Cechetto

IPC分类号： A61K39/395 ,  G01N33/574 ,  C12N5/06 ,  C07K16/30

CPC分类号： G01N33/57492 ,  A61K2039/505 ,  C07K16/30 ,  C07K16/3069 ,  C07K2317/73 ,  G01N33/57415 ,  G01N33/57419 ,  G01N33/57449

摘要： The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.

摘要翻译： 本发明涉及使用新的筛选范例来生产患者癌症疾病修饰抗体的方法。 通过使用癌细胞细胞毒性分离抗癌抗体作为终点，该方法使得可能产生用于治疗和诊断目的的抗癌抗体。 抗体可用于帮助分期和诊断癌症，并可用于治疗原发性肿瘤和肿瘤转移。 抗癌抗体可以与毒素，酶，放射性化合物和血细胞结合。

公开(公告)号：US20070031426A1

公开(公告)日：2007-02-08

申请号：US11496392

申请日：2006-07-31

申请人： David Young ,  Susan Hahn ,  Lisa Cechetto

发明人： David Young ,  Susan Hahn ,  Lisa Cechetto

IPC分类号： A61K39/395 ,  G01N33/574 ,  C12N5/06 ,  C07K16/30

CPC分类号： G01N33/57492 ,  A61K2039/505 ,  C07K16/30 ,  C07K16/3069 ,  C07K2317/73

摘要： The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.

公开(公告)号：US20070031425A1

公开(公告)日：2007-02-08

申请号：US11496390

申请日：2006-07-31

申请人： David Young ,  Susan Hahn ,  Lisa Cechetto

发明人： David Young ,  Susan Hahn ,  Lisa Cechetto

IPC分类号： A61K39/395 ,  G01N33/574 ,  C07K16/30 ,  C12N5/06

CPC分类号： G01N33/57492 ,  A61K2039/505 ,  C07K16/30 ,  C07K2317/73 ,  G01N33/57488

摘要： The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.